Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02121899 · ClinicalTrials.gov registry record
Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)
A clinical trial, sponsored by Myriad Genetic Laboratories.
- Terminated
- Registry status
- 44
- Enrollment target
NCT02121899: Clinical Trial study, sponsored by Myriad Genetic Laboratories.
NCT02121899 is a clinical trial that was terminated before completion, run by Myriad Genetic Laboratories. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02121899 was terminated before completion, sponsored by Myriad Genetic Laboratories.
- TERMINATED
- Registry status
- 44 participants
- Enrollment target
Study Summary
This registry is intended to measure the effect of myPlan Lung Cancer™ test has on influencing treatment decisions of Oncologists when added to standard clinical-pathological parameters in patients with early stage NSCLC. The sponsor is conducting two parallel registries, with one directed at Surgeons (ONC003) and the other at Oncologists (ONC006). This registry is specific to Oncologists (ONC006).
Primary Outcome
The percentage change from the recorded Pre-Test treatment recommendation by the oncologist versus the Post-Test treatment initiated.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-07-31 |
Why NCT02121899 stopped before completion
NCT02121899 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 44 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02121899 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02121899 about?
NCT02121899 is a clinical study titled "Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)". This registry is intended to measure the effect of myPlan Lung Cancer™ test has on influencing treatment decisions of Oncologists when added to standard clinical-pathological parameters in patients with early stage NSCLC. The sponsor is conducting two parallel registries, with one directed at Surge...
What is the current status of trial NCT02121899?
This trial is currently terminated. The enrollment target is 44 participants. The study started on 2015-04. Estimated completion is 2017-07-31.
Who is sponsoring clinical trial NCT02121899?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia